Imugene (ASX: IMU) chief executive officer and managing director Leslie Chong joins Small Caps to discuss the progress of the company’s phase 1 MAST trial of its novel cancer-killing virus CF33-hNIS – known as VAXINIA.

The oncolytic virus in VAXINIA has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumours in preclinical laboratory and animal models. After obtaining promising early results from trials,

Imugene is now increasing its dosage rates for a trial which is combing VAXINIA with pembrolizumab.

Imugene recently reported that 38 patients had been dosed with VAXINIA during the continuing dose escalation phase.

Overall, the study aims to recruit up to 100 patients across approximately 10 trial sites in the United States and Australia.

Articles:
https://smallcaps.com.au/imugene-novel-cancer-treatment-enters-new-phase-mast-trial/
https://smallcaps.com.au/imugene-positive-outcomes-novel-virus-trial-advanced-cancers/

For more information on Imugene:
https://smallcaps.com.au/stocks/asx-imu/

See omnystudio.com/listener for privacy information.